| Title |
Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management
|
|---|---|
| Published in |
International Journal of Hematology, November 2005
|
| DOI | 10.1532/ijh97.05034 |
| Pubmed ID | |
| Authors |
Katsuya Ikuta, Yoshihiro Torimoto, Junko Jimbo, Junki Inamura, Motohiro Shindo, Kazuya Sato, Yoshihiko Tokusashi, Naoyuki Miyokawa, Yutaka Kohgo |
| Abstract |
Imatinib mesylate is a specific inhibitor of BCR-ABL tyrosine kinase, which is now widely used for the treatment of chronic myeloid leukemia (CML) with a high efficacy. Although severe hepatic injury caused by imatinib mesylate is rare, such a side effect may force patients to discontinue taking imatinib mesylate. In the present paper, we report on the case of a 51-year-old woman with CML who experienced hepatic injury with severe hyperbilirubinemia caused by imatinib mesylate. The findings from a liver biopsy specimen and her clinical course suggested the hepatic injury to presumably have been caused by an allergic mechanism. The co-administration of prednisolone was thus tried, and she has been able to continue imatinib mesylate administration without any liver dysfunction and finally was able to obtain a complete cytogenetic response.We therefore recommend that prednisolone should be tried when severe hepatic injury caused by imatinib mesylate is observed, since it might enable such patients to continue imatinib mesylate treatment and thereby improve the prognosis in such cases. |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 1 | 20% |
| Researcher | 1 | 20% |
| Student > Postgraduate | 1 | 20% |
| Student > Doctoral Student | 1 | 20% |
| Unknown | 1 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 60% |
| Agricultural and Biological Sciences | 1 | 20% |
| Unknown | 1 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2014.
All research outputs
#20,657,128
of 25,377,790 outputs
Outputs from International Journal of Hematology
#1,000
of 1,503 outputs
Outputs of similar age
#72,566
of 76,667 outputs
Outputs of similar age from International Journal of Hematology
#7
of 9 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,503 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,667 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.